AbbVie Inc. - 8-K Filing
AbbVie revised its Q3 2026 adjusted diluted EPS guidance to $3.73-$3.77 and full-year 2026 guidance to $13.76-$13.96, including a $0.11 per share impact from acquired IPR&D and milestones expenses. (Items: 2.02 Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2026 are expecte, 9.01 Financial Statements and Exhibits(d) ExhibitsExhibit No)
Tickers: $ABBV